References

Abe T, Sumi K, Kunimatsu R Bone regeneration in a canine model of artificial jaw cleft using bone marrow-derived mesenchymal stem cells and carbonate hydroxyapatite carrier. Cleft Palate Craniofac J. 2020; 57:(2)208-217 https://doi.org/10.1177/1055665619868868

AIM OA. AIM OA Sys – veterinary monitoring. 2024. https://www.aim-oa.com/

Alves JC, Santos A, Jorge P, Carreira LM A randomized double-blinded controlled trial on the effects of photobiomodulation therapy in dogs with osteoarthritis. Am J Vet Res. 2022; 83:(8) https://doi.org/10.2460/ajvr.22.03.0036

Anderson KL, O'Neill DG, Brodbelt DC Prevalence, duration and risk factors for appendicular osteoarthritis in a UK dog population under primary veterinary care. Sci Rep. 2018; 8:(1) https://doi.org/10.1038/s41598-018-23940-z

Canine Arthritis Management. Your dog, arthritis and how CAM can help. 2024. https://caninearthritis.co.uk

Caplan AI Mesenchymal stem cells. J Orthop Res. 1991; 9:(5)641-650 https://doi.org/10.1002/jor.1100090504

Caplan AI Why are MSCs therapeutic? New data: new insight. J Pathol. 2009; 217:(2)318-324 https://doi.org/10.1002/path.2469

Caplan AI Mesenchymal stem cells: time to change the name!.. Stem Cells Transl Med. 2017; 6:(6)1445-1451 https://doi.org/10.1002/sctm.17-0051

Chandrasekaran A, Thomsen BB, Agerholm JS Neural derivates of canine induced pluripotent stem cells-like cells from a mild cognitive impairment dog. Front Vet Sci. 2021; 8 https://doi.org/10.3389/fvets.2021.725386

Daems R, Van Hecke L, Schwarzkopf I A feasibility study on the use of equine chondrogenic induced mesenchymal stem cells as a treatment for natural occurring osteoarthritis in dogs. Stem Cells Int. 2019; 2019 https://doi.org/10.1155/2019/4587594

Duan X, Zhu X, Dong X Repair of large osteochondral defects in a beagle model with a novel type I collagen/glycosaminoglycanporous titanium biphasic scaffold. Mater Sci Eng C Mater Biol Appl. 2013; 33:(7)3951-3957 https://doi.org/10.1016/j.msec.2013.05.040

Franklin SP, Stoker AM, Bozynski CC Comparison of platelet-rich plasma, stromal vascular fraction (SVF), or SVF with an injectable PLGA nanofiber scaffold for the treatment of osteochondral injury in dogs. J Knee Surg. 2018; 31:(7)686-697 https://doi.org/10.1055/s-0037-1606575

Gooch A, Zhang P, Hu Z Interim report on the effective intraperitoneal therapy of insulin-dependent diabetes mellitus in pet dogs using ``neoislets," aggregates of adipose stem and pancreatic islet cells (INAD 012-776). PLoS One. 2019; 14:(9) https://doi.org/10.1371/journal.pone.0218688

Harman R, Carlson K, Gaynor J A prospective, randomized, masked, and placebo-controlled efficacy study of intraarticular allogeneic adipose stem cells for the treatment of osteoarthritis in dogs. Front Vet Sci. 2016; 3 https://doi.org/10.3389/fvets.2016.00081

Humenik F, Maloveska M, Hudakova N A comparative study of canine mesenchymal stem cells isolated from different sources. Animals (Basel). 2022; 12:(12) https://doi.org/10.3390/ani12121502

Kim YS, Kwon OR, Choi YJ, Suh DS, Heo DB, Koh YG Comparative matched-pair analysis of the injection versus implantation of mesenchymal stem cells for knee osteoarthritis. Am J Sports Med. 2015; 43:(11)2738-2746 https://doi.org/10.1177/0363546515599632

Kriston-Pál É, Czibula Á, Gyuris Z Characterization and therapeutic application of canine adipose mesenchymal stem cells to treat elbow osteoarthritis. Can J Vet Res. 2017; 81:(1)73-78

Leibacher J, Henschler R Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells. Stem Cell Res Ther. 2016; 7 https://doi.org/10.1186/s13287-015-0271-2

Mocchi M, Dotti S, Bue MD Veterinary regenerative medicine for musculoskeletal disorders: can mesenchymal stem/stromal cells and their secretome be the new frontier?.. Cells. 2020; 9:(6) https://doi.org/10.3390/cells9061453

Mokbel A, El-Tookhy O, Shamaa AA, Sabry D, Rashed L, Mostafa A Homing and efficacy of intra-articular injection of autologous mesenchymal stem cells in experimental chondral defects in dogs. Clin Exp Rheumatol. 2011a; 29:(2)275-284

Mokbel A, El-Tookhy OS, Shamaa AA, Rashed LA, Sabry D, El Sayed AM Homing and reparative effect of intra-articular injection of autologous mesenchymal stem cells in osteoarthritic animal model. BMC Musculoskelet Disord. 2011b; 12 https://doi.org/10.1186/1471-2474-12-259

Mund SJK, Kawamura E, Awang-Junaidi AH Homing and engraftment of intravenously administered equine cord blood-derived multipotent mesenchymal stromal cells to surgically created cutaneous wound in horses: a pilot project. Cells. 2020; 9:(5) https://doi.org/10.3390/cells9051162

Najar M, Raicevic G, Boufker HI Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng Part A. 2010; 16:(11)3537-3546 https://doi.org/10.1089/ten.TEA.2010.0159

Olsen A, Johnson V, Webb T, Santangelo KS, Dow S, Duerr FM Evaluation of intravenously delivered allogeneic mesenchymal stem cells for treatment of elbow osteoarthritis in dogs: a pilot study. Vet Comp Orthop Traumatol. 2019; 32:(3)173-181 https://doi.org/10.1055/s-0039-1678547

Olsson DC, Teixeira BL, Jeremias TDS Administration of mesenchymal stem cells from adipose tissue at the hip joint of dogs with osteoarthritis: a systematic review. Res Vet Sci. 2021; 135:495-503 https://doi.org/10.1016/j.rvsc.2020.11.014

Pérez-Merino EM, Usón-Casaús JM, Zaragoza-Bayle C Safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells for treatment of dogs with inflammatory bowel disease: clinical and laboratory outcomes. Vet J. 2015; 206:(3)385-390 https://doi.org/10.1016/j.tvjl.2015.08.003

Phinney DG, Pittenger MF Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017; 35:(4)851-858 https://doi.org/10.1002/stem.2575

Pye C, Bruniges N, Peffers M, Comerford E Advances in the pharmaceutical treatment options for canine osteoarthritis. J Small Anim Pract. 2022; 63:(10)721-738 https://doi.org/10.1111/jsap.13495

Pye C, Clark N, Bruniges N, Peffers M, Comerford E Current evidence for non-pharmaceutical, non-surgical treatments of canine osteoarthritis. J Small Anim Pract. 2024; 65:(1)3-23 https://doi.org/10.1111/jsap.13670

Qiang Y, Yanhong Z, Jiang P Xenoimplantation of an extracellularmatrix-derived, biphasic, cell-scaffold construct for repairing a large femoral-head high-load-bearing osteochondral defect in a canine model. ScientificWorldJournal. 2014; 2014 https://doi.org/10.1155/2014/127084

Scharstuhl A, Schewe B, Benz K, Gaissmaier C, Bühring HJ, Stoop R Chondrogenic potential of human adult mesenchymal stem cells is independent of age or osteoarthritis etiology. Stem Cells. 2007; 25:(12)3244-3251 https://doi.org/10.1634/stemcells.2007-0300

Spees JL, Olson SD, Whitney MJ, Prockop DJ Mitochondrial transfer between cells can rescue aerobic respiration. Proc Natl Acad Sci USA. 2006; 103:(5)1283-1288 https://doi.org/10.1073/pnas.0510511103

Tofiño-Vian M, Guillén MI, Alcaraz MJ Extracellular vesicles: a new therapeutic strategy for joint conditions. Biochem Pharmacol. 2018; 153:134-146 https://doi.org/10.1016/j.bcp.2018.02.004

Ueda S, Shimasaki M, Ichiseki T Prevention of glucocorticoidassociated osteonecrosis by intravenous administration of mesenchymal stem cells in a rabbit model. BMC Musculoskelet Disord. 2017; 18:(1) https;//doi.org/10.1186/s12891-017-1837-1

Ullah M, Liu DD, Thakor AS Mesenchymal stromal cell homing: mechanisms and strategies for improvement. iScience. 2019; 15:421-438 https://doi.org/10.1016/j.isci.2019.05.004

Villatoro AJ, Hermida-Prieto M, Fernández V Allogeneic adiposederived mesenchymal stem cell therapy in dogs with refractory atopic dermatitis: clinical efficacy and safety. Vet Rec. 2018; 183:(21) https://doi.org/10.1136/vr.104867

Voga M, Adamic N, Vengust M, Majdic G Stem cells in veterinary medicine-current state and treatment options. Front Vet Sci. 2020; 7 https://doi.org/10.3389/fvets.2020.00278

Wang M, Liang C, Hu H Intraperitoneal injection (IP), intravenous injection (IV) or anal injection (AI)? Best way for mesenchymal stem cells transplantation for colitis. Sci Rep. 2016; 6 https://doi.org/10.1038/srep30696

Yang Q, Peng J, Lu SB Evaluation of an extracellular matrix-derived acellular biphasic scaffold/cell construct in the repair of a large articular high-load-bearing osteochondral defect in a canine model. Chin Med J (Engl). 2011; 124:(23)3930-3938

Zhu Y, Liu T, Song K, Fan X, Ma X, Cui Z Adipose-derived stem cell: a better stem cell than BMSC. Cell Biochem Funct. 2008; 26:(6)664-675 https://doi.org/10.1002/cbf.1488

Stem cells in canine osteoarthritis. Part 1: sources, effects and modes of action

02 March 2025
16 mins read
Volume 30 · Issue 3
Figure 1. 
Stem cells in vitro – microscope photograph (×100).
Figure 1. Stem cells in vitro – microscope photograph (×100).

Abstract

Osteoarthritis represents the most prevalent joint pathology diagnosed in both human and veterinary medicine, and it is characterised by progressive degenerative changes and remodelling of synovial joints. These pathological alterations lead to compromised biomechanical function and nociceptive pain responses. In humans, osteoarthritis is associated with severe pain and can evolve into a chronic, debilitating condition. The aetiology is often multifactorial, involving systemic and local biomechanical disruptions. Clinical observations in canines, such as gait abnormalities and a favourable response to analgesic interventions, suggest a comparable pain experience and effect on quality of life in affected dogs.

Osteoarthritis is widely recognised as a complex, multifactorial disease with a significant genetic predisposition. In canine populations, the manifestation and severity of osteoarthritis is also influenced by various lifestyle factors, including diet and physical activity levels. In veterinary contexts, osteoarthritis is frequently classified as secondary, emerging subsequent to primary joint abnormalities, such as dysplasia, cranial cruciate ligament rupture or patellar luxation, as well as primary trauma. These primary conditions are hypothesised to precipitate the onset of osteoarthritic changes. The precise epidemiological data regarding the proportion of canines that develop secondary osteoarthritis because of these predisposing factors remain undetermined.

The prevalence of osteoarthritis in dogs ranges from 6.6% (based on primary care data) to 20% (based on referral data) in the UK dog population. Estimates from North America report prevalence from 20% in dogs older than one year up to 80% in dogs older than eight years, based on radiographic and clinical data from referral clinics (Anderson et al, 2018).

Register now to continue reading

Thank you for visiting UK-VET Companion Animal and reading some of our peer-reviewed content for veterinary professionals. To continue reading this article, please register today.